Bio-Rad Laboratories, a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies with the introduction of six antibodies specific to dupilumab (Dupixent) and the addition of new evolocumab (Repatha), ipilimumab (Yervoy), and secukinumab (Cosentyx) antibodies.
Early smoking tied to increased respiratory problems in young adults
People who started smoking under the age of 18 are more likely to experience respiratory symptoms, such as wheezing and phlegm, in their 20s, according
September 10, 2024